We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
US Stem Cell Inc (CE) | USOTC:USRM | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2016
OR
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _____ to _____
|
Florida
|
65-0945967
|
(State or other jurisdiction of incorporation or organization
|
(I.R.S. Employer Identification No.)
|
Large accelerated filer
☐
|
Accelerated filer
☐
|
Non-accelerated filer
☐
|
Smaller reporting company
☒
|
(Do not check if a smaller reporting company)
|
|
PART I.
|
FINANCIAL INFORMATION
|
|
|
|
|
|
|
|
|
|
ITEM 1.
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
5
|
|
|
|
|
|
|
|
|
|
6
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
8-26
|
|
|
|
|
|
|
|
ITEM 2.
|
|
27-36
|
|
|
ITEM 3.
|
|
36
|
|
|
ITEM 4.
|
|
36
|
|
|
|
|
|
|
PART II.
|
OTHER INFORMATION
|
|
|
|
|
|
|
|
|
|
ITEM 1.
|
|
37
|
|
|
ITEM 1A.
|
|
37
|
|
|
ITEM 2.
|
|
37
|
|
|
ITEM 3.
|
|
37
|
|
|
ITEM 4.
|
|
38
|
|
|
ITEM 5.
|
|
38
|
|
|
ITEM 6.
|
|
38
|
|
|
|
|
|
|
|
|
42
|
||
EX-31.01 | Management Certification | |||
EX-32.01
|
||||
U.S. STEM CELL, INC.
|
||||||||
March 31,
|
December 31,
|
|||||||
2016
|
2015
|
|||||||
(unaudited)
|
||||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
275,404
|
$
|
58,372
|
||||
Accounts receivable, net
|
48,756
|
35,032
|
||||||
Inventory
|
30,538
|
17,406
|
||||||
Prepaid and other
|
-
|
4,832
|
||||||
Total current assets
|
354,698
|
115,642
|
||||||
Property and equipment, net
|
12,960
|
14,172
|
||||||
Other assets
|
||||||||
Investments
|
54,998
|
89,139
|
||||||
Deposits
|
10,160
|
10,160
|
||||||
Total assets
|
$
|
432,816
|
$
|
229,113
|
||||
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
||||||||
Current liabilities:
|
||||||||
Accounts payable, including $60,187 and $104,089 to related parties, respectively
|
$
|
1,416,827
|
$
|
1,503,501
|
||||
Accrued expenses
|
754,110
|
726,751
|
||||||
Advances, related party
|
54,901
|
106,505
|
||||||
Deferred revenue
|
78,063
|
71,961
|
||||||
Deposits
|
465,286
|
465,286
|
||||||
Promissory note, short term portion, net of debt discount of $76,792 and $78,864 respectively
|
73,208
|
71,136
|
||||||
Notes payable, related party
|
1,691,454
|
1,727,022
|
||||||
Notes payable, net of debt discount of $348,593 and $249,205, respectively
|
726,723
|
608,502
|
||||||
Derivative liabilities
|
626,828
|
423,927
|
||||||
Total current liabilities
|
5,887,400
|
5,704,591
|
||||||
Long term debt:
|
||||||||
Promissory note, long term portion, net of debt discount of $222,364 and $240,522, respectively
|
1,250,398
|
1,232,241
|
||||||
Notes payable, long term portion
|
983,448
|
983,727
|
||||||
Note payable, long term portion, related party
|
-
|
30,000
|
||||||
Total long term debt
|
2,233,846
|
2,245,968
|
||||||
Total liabilities
|
8,121,246
|
7,950,559
|
||||||
Commitments and contingencies
|
-
|
-
|
||||||
Stockholders' deficit:
|
||||||||
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding
|
20,000
|
20,000
|
||||||
Common stock, par value $0.001; 2,000,000,000 shares authorized, 2,841,049 and 1,813,689 shares issued and 2,745,588 and 1,728,478 outstanding as of March 31, 2016 and December 31, 2015, respectively
|
2,841
|
1,814
|
||||||
Additional paid in capital
|
114,958,240
|
114,555,110
|
||||||
Treasury stock, 95,461 and 85,211 shares, respectively
|
(229,813
|
)
|
(221,996
|
)
|
||||
Accumulated deficit
|
(122,439,698
|
)
|
(122,076,374
|
)
|
||||
Total stockholders' deficit
|
(7,688,430
|
)
|
(7,721,446
|
)
|
||||
Total liabilities and stockholders' deficit
|
$
|
432,816
|
$
|
229,113
|
U.S. STEM CELL, INC.
|
||||||||
(unaudited)
|
||||||||
Three months ended March 31,
|
||||||||
2016
|
2015
|
|||||||
Revenue:
|
||||||||
Products
|
$
|
501,425
|
$
|
285,349
|
||||
Services
|
209,521
|
204,208
|
||||||
Total revenue
|
710,946
|
489,557
|
||||||
Cost of sales
|
154,382
|
293,415
|
||||||
Gross profit
|
556,564
|
196,142
|
||||||
Cost and operating expenses:
|
||||||||
Research and development
|
3,495
|
2,500
|
||||||
Marketing, general and administrative
|
565,806
|
999,987
|
||||||
Depreciation and amortization
|
1,213
|
1,301
|
||||||
Total operating expenses
|
570,514
|
1,003,788
|
||||||
Net loss from operations
|
(13,950
|
)
|
(807,646
|
)
|
||||
Other income (expenses):
|
||||||||
(Loss) gain on settlement of debt
|
(21,293
|
)
|
59,430
|
|||||
Gain on disposal of equipment
|
500
|
-
|
||||||
Gain on change of fair value of derivative liability
|
14,506
|
122,724
|
||||||
Income from equity investment
|
15,859
|
3,966
|
||||||
Other income
|
2,456
|
3,151
|
||||||
Interest expense
|
(361,402
|
)
|
(429,842
|
)
|
||||
Total other income (expenses)
|
(349,374
|
)
|
(240,571
|
)
|
||||
Net loss before income taxes
|
(363,324
|
)
|
(1,048,217
|
)
|
||||
Income taxes (benefit)
|
-
|
-
|
||||||
NET LOSS
|
$
|
(363,324
|
)
|
$
|
(1,048,217
|
)
|
||
Net loss per common share, basic and diluted
|
$
|
(0.18
|
)
|
$
|
(1.67
|
)
|
||
Weighted average number of common shares outstanding, basic and diluted
|
2,054,269
|
626,644
|
U.S. STEM CELL, INC.
|
|
THREE MONTHS ENDED MARCH 31, 2016
|
|
(unaudited)
|
Additional
|
||||||||||||||||||||||||||||||||
Preferred stock
|
Common stock
|
Paid in
|
Treasury
|
Accumulated
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Deficit
|
Total
|
|||||||||||||||||||||||||
Balance, January 1, 2016
|
20,000,000
|
$
|
20,000
|
1,813,689
|
$
|
1,814
|
$
|
114,555,110
|
$
|
(221,996
|
)
|
$
|
(122,076,374
|
)
|
$
|
(7,721,446
|
)
|
|||||||||||||||
Common stock issued in settlement of accounts payable and accrued interest
|
-
|
-
|
16,753
|
17
|
15,664
|
-
|
-
|
15,681
|
||||||||||||||||||||||||
Common stock issued in connection with settlement of other debt
|
-
|
-
|
996,001
|
996
|
310,200
|
-
|
-
|
311,196
|
||||||||||||||||||||||||
Common stock issued in settlement of note payable, related party
|
-
|
-
|
14,606
|
14
|
6,558
|
-
|
-
|
6,572
|
||||||||||||||||||||||||
Purchase of 10,250 shares of Company's common stock at average cost of $0.76 per share
|
-
|
-
|
-
|
-
|
-
|
(7,817
|
)
|
-
|
(7,817
|
)
|
||||||||||||||||||||||
Stock based compensation
|
-
|
-
|
-
|
-
|
70,708
|
-
|
-
|
70,708
|
||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
(363,324
|
)
|
(363,324
|
)
|
||||||||||||||||||||||
Balance, March 31, 2016
|
20,000,000
|
$
|
20,000
|
2,841,049
|
$
|
2,841
|
$
|
114,958,240
|
$
|
(229,813
|
)
|
$
|
(122,439,698
|
)
|
$
|
(7,688,430
|
)
|
U.S. STEM CELL, INC.
|
||||||||
(unaudited)
|
||||||||
Three months ended March 31,
|
||||||||
2016
|
2015
|
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
Net loss
|
$
|
(363,324
|
)
|
$
|
(1,048,217
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
1,213
|
1,301
|
||||||
Bad debt expense
|
21,816
|
-
|
||||||
Discount on convertible debt
|
207,177
|
231,795
|
||||||
Change in fair value of derivative liability
|
(14,506
|
)
|
(122,724
|
)
|
||||
Loss (gain) on settlement of debt
|
21,293
|
(59,430
|
)
|
|||||
Gain on sale of equipment
|
(500
|
)
|
-
|
|||||
Common stock issued in settlement of litigation
|
-
|
59,850
|
||||||
Non cash payment of interest
|
77,895
|
88,578
|
||||||
Income on equity investments
|
(15,859
|
)
|
(3,966
|
)
|
||||
Stock based compensation
|
70,708
|
194,936
|
||||||
(Increase) decrease in:
|
||||||||
Receivables
|
(35,540
|
)
|
16,920
|
|||||
Inventory
|
(13,132
|
)
|
-
|
|||||
Prepaid and other current assets
|
4,832
|
8,997
|
||||||
Increase (decrease) in:
|
||||||||
Accounts payable
|
(62,869
|
)
|
114,452
|
|||||
Accrued expenses
|
32,621
|
94,024
|
||||||
Deferred revenue
|
6,102
|
39,233
|
||||||
Net cash used in operating activities
|
(62,073
|
)
|
(384,251
|
)
|
||||
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
Proceeds from (payments to) equity investments
|
50,000
|
(5,000
|
)
|
|||||
Proceeds from sale of property and equipment
|
500
|
-
|
||||||
Purchase of treasury stock
|
(7,817
|
)
|
-
|
|||||
Acquisitions of property and equipment
|
-
|
(894
|
)
|
|||||
Net cash provided by (used in) investing activities
|
42,683
|
(5,894
|
)
|
|||||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
Proceeds from issuance of common stock, net
|
-
|
299,848
|
||||||
Proceeds from notes payable
|
407,896
|
180,000
|
||||||
Repayments of related party advances, net
|
(35,000
|
)
|
-
|
|||||
Repayments of related party notes
|
(65,568
|
)
|
-
|
|||||
Repayments of notes payable
|
(70,906
|
)
|
(55,403
|
)
|
||||
Net cash provided in financing activities
|
236,422
|
424,445
|
||||||
Net increase in cash and cash equivalents
|
217,032
|
34,300
|
||||||
Cash and cash equivalents, beginning of period
|
58,372
|
36,674
|
||||||
Cash and cash equivalents, end of period
|
$
|
275,404
|
$
|
70,974
|
||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
|
||||||||
Interest paid
|
$
|
13,364
|
$
|
108,471
|
||||
Income taxes paid
|
$
|
-
|
$
|
-
|
||||
Non-cash financing activities:
|
||||||||
Common stock issued in settlement of notes payable
|
$
|
120,445
|
$
|
231,727
|
||||
Common stock issued in settlement of accounts payable
|
$
|
5,953
|
$
|
41,782
|
||||
Common stock issued in settlement of note payable, related party
|
$
|
10,000
|
$
|
-
|
|
March 31,
2016
|
March 31,
2015
|
||||||
Convertible debt
|
7,822,689
|
107,163
|
||||||
Series A convertible preferred stock
|
20,000,000
|
20,000,000
|
||||||
Options to purchase common stock
|
555,815
|
73,900
|
||||||
Warrants to purchase common stock
|
139,334
|
150,775
|
||||||
Totals
|
28,517,838
|
20,331,838
|
|
March 31,
2016
|
December 31,
2015
|
||||||
Laboratory and medical equipment
|
$
|
329,638
|
$
|
353,253
|
||||
Furniture, fixtures and equipment
|
130,410
|
130,410
|
||||||
Computer equipment
|
48,788
|
48,788
|
||||||
Leasehold improvements
|
362,046
|
362,046
|
||||||
|
870,882
|
894,497
|
||||||
Less accumulated depreciation and amortization
|
(857,922
|
)
|
(880,325
|
)
|
||||
|
$
|
12,960
|
$
|
14,172
|
|
March 31,
2016
|
December 31,
2015
|
||||||
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest
|
$
|
86,311
|
$
|
64,199
|
||||
Interest payable on notes payable
|
503,256
|
467,664
|
||||||
Vendor accruals and other
|
146,451
|
147,244
|
||||||
Employee commissions, compensation, etc.
|
18,092
|
47,644
|
||||||
|
$
|
754,110
|
$
|
726,751
|
|
March 31,
2016
|
December 31,
2015
|
||||||
Seaside Bank note payable.
|
$
|
980,000
|
$
|
980,000
|
||||
Hunton & Williams notes payable
|
384,972
|
384,972
|
||||||
Daniel James Management notes payable
|
100,000
|
75,000
|
||||||
Fourth Man, LLC notes payable
|
50,000
|
77,450
|
||||||
Magna Group notes payable
|
344,505
|
125,000
|
||||||
Power Up Lending Group notes payable
|
270,743
|
194,235
|
||||||
Equipment finance lease
|
4,285
|
4,777
|
||||||
Total notes payable
|
2,134,505
|
1,841,434
|
||||||
Less unamortized debt discount
|
(424,334
|
)
|
(249,205
|
)
|
||||
Total notes payable net of unamortized debt discount
|
1,710,171
|
1,592,229
|
||||||
Less current portion
|
(726,723
|
)
|
(608,502
|
)
|
||||
Long term portion
|
$
|
983,448
|
$
|
983,727
|
|
March 31,
2016
|
December 31,
2015
|
||||||
Note payable, Beverly Murphy
|
50,000
|
50,000
|
||||||
Note payable, Mr. Tomas
|
216,682
|
252,250
|
||||||
Note payable, Mr. Tomas
|
375,000
|
375,000
|
||||||
Note payable, Mr. Tomas
|
500,000
|
500,000
|
||||||
Note payable, Ms. Comella
|
287,772
|
287,772
|
||||||
Total
|
$
|
1,429,454
|
$
|
1,465,022
|
|
Shares
|
Weighted-
Average
Exercise Price
|
Weighted-
Average
Remaining
Contractual
Term (in years)
|
|||||||||
|
||||||||||||
Options outstanding at January 1, 2015
|
66,933
|
$
|
56.00
|
8.9
|
||||||||
Granted
|
489,116
|
$
|
1.98
|
10.00
|
||||||||
Exercised
|
—
|
|||||||||||
Forfeited/Expired
|
(229
|
)
|
$
|
5,103.28
|
||||||||
Options outstanding at December 31, 2015
|
555,820
|
$
|
6.43
|
9.6
|
||||||||
Granted
|
—
|
|||||||||||
Exercised
|
—
|
|||||||||||
Forfeited/Expired
|
(5
|
)
|
$
|
4,674.36
|
||||||||
Options outstanding at March 31, 2016
|
555,815
|
$
|
6.38
|
9.4
|
||||||||
Options exercisable at March 31, 2016
|
511,655
|
$
|
5.56
|
9.4
|
||||||||
Available for grant at March 31, 2016
|
7,383,070
|
Options Outstanding
|
Options Exercisable
|
||||||||||||||||||||||
Shares
|
Weighted-
Average
Remaining
Contractual
Term
|
Weighted-
Average
Exercise
Price
|
Shares
|
Weighted-
Average
Exercise
Price
|
|||||||||||||||||||
$
|
0.00 – $20.00
|
534,706
|
9.4
|
$
|
3.31
|
501,682
|
$
|
2.72
|
|||||||||||||||
$
|
20.01 – $30.00
|
19,849
|
8.3
|
$
|
26.96
|
8,713
|
$
|
26.94
|
|||||||||||||||
$
|
30.01 – $100.00
|
300
|
5.4
|
$
|
70.00
|
300
|
$
|
70.00
|
|||||||||||||||
$ |
>100.00
|
960 | 3.8 | $ | 1,270.73 | 960 | $ | 1,270.73 | |||||||||||||||
555,815
|
9.4
|
$
|
6.39
|
511,655
|
$
|
5.56
|
|
Shares
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Term (in years)
|
|||||||||
Outstanding at January 1, 2015
|
150,620
|
$
|
170.00
|
6.6
|
||||||||
Issued
|
2,072
|
$
|
19.98
|
8.18
|
||||||||
Exercised
|
-
|
|
||||||||||
Expired
|
(13,325
|
)
|
$
|
24.00
|
||||||||
Outstanding at December 31, 2015
|
139,367
|
$
|
182.26
|
6.3
|
||||||||
Issued
|
-
|
|||||||||||
Exercised
|
-
|
|
||||||||||
Expired
|
(33
|
)
|
$
|
7,690.00
|
||||||||
Outstanding at March 31, 2016
|
139,334
|
$
|
180.48
|
6.0
|
||||||||
Exercisable at March 31, 2016
|
134,789
|
$
|
97.54
|
6.0
|
Warrants Outstanding
|
Warrants Exercisable
|
|||||||||||||||||||||
Shares
|
Weighted-
Average
Remaining
Contractual
Term
|
Weighted-
Average
Exercise
Price
|
Shares
|
Weighted-
Average
Exercise
Price
|
||||||||||||||||||
$
|
0.01 – $20.00
|
94,108
|
6.5
|
$
|
15.54
|
94,108
|
$
|
15.54
|
||||||||||||||
$
|
20.01 – $30.00
|
29,743
|
5.8
|
$
|
24.52
|
28,743
|
$
|
24.62
|
||||||||||||||
$
|
30.01 – $40.00
|
628
|
1.4
|
$
|
40.00
|
628
|
$
|
40.00
|
||||||||||||||
$
|
40.01 - $50.00
|
6,253
|
2.9
|
$
|
48.36
|
4,253
|
$
|
48.49
|
||||||||||||||
$
|
50.01 – $60.00
|
543
|
1.7
|
$
|
60.00
|
543
|
$
|
60.00
|
||||||||||||||
$ | > 60.00 | 8,059 | 3.9 | $ | 2,803.74 | 6,514 | $ | 1,644.81 | ||||||||||||||
139,334
|
6.0
|
$
|
180.48
|
134,789
|
$
|
97.54
|
Period ending December 31,
|
||||
2016 (nine months)
|
$
|
65,756
|
||
2017
|
87,674
|
|||
2018
|
87,674
|
|||
2019
|
58,448
|
|||
Total
|
$
|
299,552
|
|
Warrant
Liability
|
Debt
Derivative
|
||||||
Balance, December 31, 2014
|
149,920
|
$
|
591,351
|
|||||
Total (gains) losses
|
||||||||
Initial fair value of debt derivative at note issuance
|
—
|
1,097,379
|
||||||
Mark-to-market at December 31, 2015:
|
(137,711
|
)
|
122,616
|
|||||
Transfers out of Level 3 upon conversion and settlement of notes
|
—
|
(1,399,628
|
)
|
|||||
Balance, December 31, 2015
|
12,209
|
411,718
|
||||||
Total (gains) losses
|
||||||||
Initial fair value of debt derivative at note issuance
|
—
|
402,895
|
||||||
Mark-to-market at March 31, 2016:
|
(10,654
|
)
|
(3,852
|
)
|
||||
Transfers out of Level 3 upon conversion or payoff of notes payable
|
—
|
(185,488
|
)
|
|||||
Balance, March 31, 2016
|
$
|
1,555
|
$
|
625,273
|
||||
Net gain for the period included in earnings relating to the liabilities held at March 31, 2016
|
$
|
10,654
|
$
|
3,852
|
●
|
our financial position and historical financial performance;
|
●
|
arm’s length sales of our common stock;
|
●
|
the development status of our product candidates;
|
●
|
the business risks we face;
|
●
|
vesting restrictions imposed upon the equity awards; and
|
●
|
an evaluation and benchmark of our competitors; and
|
●
|
prospects of a liquidity event.
|
Exhibit No.
|
Exhibit Description
|
3.1(6)
|
Amended and Restated Articles of Incorporation of the registrant, as amended
|
3.2(9)
|
Articles of Amendment to the Articles of Incorporation of the registrant
|
3.3(37)
|
Articles of Amendment to the Articles of Incorporation of the registrant
|
3.4 (8)
|
Amended and Restated Bylaws
|
4.1(5)
|
Loan and Security Agreement, dated as of May 31, 2007 by and between BlueCrest Capital Finance, L.P. and the registrant
|
4.2(12)
|
Notice of Event of Default, from BlueCrest Venture Finance Master Fund Limited to the Company, dated January 28, 2009
|
4.3(12)
|
Notice of Acceleration, from BlueCrest Venture Finance Master Fund Limited to the Company, dated February 2, 2009
|
4.4(13)
|
Amendment to Loan and Security Agreement, between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
|
4.5(13)
|
Grant of Security Interest (Patents), between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
|
4.6(13)
|
Security Agreement (Intellectual Property), between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
|
4.7(13)
|
Subordination Agreement, by Hunton & Williams, LLP in favor of BlueCrest Venture Finance Master Fund Limited, entered into and effective April 2, 2009
|
4.8(13)
|
Amended and Restated Promissory Note, dated April 2, 2009, by the Company to BlueCrest Venture Finance Master Fund Limited
|
4.9(13)
|
Warrant to purchase 1,315,542 shares of the registrant’s common stock, dated April 2, 2009, issued to BlueCrest Venture Finance Master Fund Limited
|
4.10(14)
|
Warrant to purchase 451,043 shares of the registrant’s common stock, dated April 2, 2009, issued to Rogers Telecommunications Limited
|
4.11(14)
|
Warrant to purchase 173,638 shares of the registrant’s common stock, dated April 2, 2009, issued to Hunton & Williams, LLP
|
4.12(4)
|
Warrant to purchase shares of the registrant’s common stock issued to Howard J. Leonhardt and Brenda Leonhardt
|
4.12(19)
|
10% Convertible Promissory Note Due July 23, 2010, in the amount of $20,000, payable to Dana Smith
|
4.13(19)
|
10% Convertible Promissory Note Due July 23, 2010, in the amount of $100,000, payable to Bruce Meyers
|
4.14(19)
|
Registration Rights Agreement, dated July 23, 2009
|
4.15(4)
|
Warrant to purchase shares of the registrant’s common stock issued to the R&A Spencer Family Limited Partnership
|
4.15(19)
|
Subordination Agreement, dated July 23, 2009
|
4.16(19)
|
Note Purchase Agreement, dated July 23, 2009
|
4.17(19)
|
Closing Confirmation of Conversion Election, dated July 23, 2009
|
4.20(6)
|
Warrant to purchase shares of the registrant’s common stock issued to Samuel S. Ahn, M.D.
|
4.23(7)
|
Warrant to purchase shares of the registrant’s common stock issued to Howard and Brenda Leonhardt
|
4.27(11)
|
Form of Warrant Agreement for October 2008 Private Placement
|
4.30(19)
|
10% Convertible Promissory Note Due July 23, 2010, in the amount of $100,000, payable to Bruce Meyers
|
4.31 (34)
|
Series A Convertible Preferred Stock
|
4.32 (35)
|
Amendment to the Series A Convertible Preferred Stock
|
10.1**(1)
|
1999 Officers and Employees Stock Option Plan
|
10.2**(1)
|
1999 Directors and Consultants Stock Option Plan
|
10.3(1)
|
Form of Option Agreement under 1999 Officers and Employees Stock Option Plan
|
10.4(3)
|
Form of Option Agreement under 1999 Directors and Consultants Stock Option Plan
|
10.5**(4)
|
Employment Letter Agreement between the registrant and Scott Bromley, dated August 24, 2006.
|
10.6(1)
|
Lease Agreement between the registrant and Sawgrass Business Plaza, LLC, as amended, dated November 14, 2006.
|
10.7(1)
|
Asset Purchase Agreement between the registrant and Advanced Cardiovascular Systems, Inc., dated June 24, 2003.
|
10.8(4)
|
Conditionally Exclusive License Agreement between the registrant, Dr. Peter Law and Cell Transplants International, LLC, dated February 7, 2000, as amended.
|
10.9(4)
|
Loan Guarantee, Payment and Security Agreement, dated as of June 1, 2007, by and between the registrant, Howard J. Leonhardt and Brenda Leonhardt
|
10.10(4)
|
Loan Guarantee, Payment and Security Agreement, dated as of June 1, 2007, by and between the registrant and William P. Murphy Jr., M.D.
|
10.11(4)
|
Loan Agreement, dated as of June 1, 2007, by and between the registrant and Bank of America, N.A.
|
10.13(4)
|
Warrant to purchase shares of the registrant’s common stock issued to Howard J. Leonhardt and Brenda Leonhardt
|
10.14(4)
|
Warrant to purchase shares of the registrant’s common stock issued to William P. Murphy, Jr., M.D.
|
10.16(4)
|
Material Supply Agreement, dated May 10, 2007, by and between the registrant and Biosense Webster
|
10.17(5)
|
Warrant to purchase shares of the registrant’s common stock issued to BlueCrest Capital Finance, L.P.
|
10.18(6)
|
Loan Guarantee, Payment and Security Agreement, dated as of September 12, 2007, by and between the registrant and Samuel S. Ahn, M.D.
|
10.19(6)
|
Loan Guarantee, Payment and Security Agreement, dated as of September 12, 2007, by and between the registrant and Dan Marino
|
10.21(6)
|
Loan Guarantee, Payment and Security Agreement, dated as of September 19, 2007, by and between the registrant and Jason Taylor
|
10.22(7)
|
Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and Howard and Brenda Leonhardt
|
10.24(7)
|
Second Amendment to Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and Howard and Brenda Leonhardt
|
10.25(7)
|
Second Amendment to Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and William P. Murphy, Jr., M.D.
|
10.26**(10)
|
U.S. Stem Cell, Inc. Omnibus Equity Compensation Plan
|
10.28(11)
|
Form of Registration Rights Agreement for October 2008 Private Placement
|
10.29(19)
|
10% Convertible Promissory Note Due July 23, 2010, in the amount of $20,000, payable to Dana Smith
|
10.31(19)
|
Registration Rights Agreement, dated July 23, 2009
|
10.32(19)
|
Subordination Agreement, dated July 23, 2009
|
10.33(19)
|
Note Purchase Agreement, dated July 23, 2009
|
10.34(19)
|
Closing Confirmation of Conversion Election, dated July 23, 2009
|
10.35**(20)
|
Amended and Restated 1999 Directors and Consultants Stock Option Plan
|
10.36(21)
|
Preliminary Commitment Letter with Seaside National Bank and Trust, dated September 30, 2010.
|
10.37(22)
|
Loan Agreement with Seaside National Bank and Trust, dated October 25, 2010.
|
10.38(22)
|
Promissory Note with Seaside National Bank and Trust, dated October 25, 2010.
|
10.39(22)
|
Amended and Restated Loan and Security Agreement with BlueCrest Venture Finance Master Fund Limited, dated October 25, 2010.
|
10.40(23)
|
Form of Subscription Agreement, executed November 30, 2010.
|
10.41(23)
|
Form of Common Stock Purchase Warrant, issued November 30, 2010.
|
10.42(23)
|
Form of Registration Rights Agreement, dated November 30, 2010.
|
10.43(24)
|
Unsecured Convertible Promissory Note for $25,000, with Magna Group, LLC, dated January 3, 2011.
|
10.44(24)
|
Promissory Note for $139,728.82 with Magna Group, LLC, dated January 3, 2011.
|
10.45(24)
|
Securities Purchase Agreement with Magna Group, LLC, dated January 3, 2011.
|
10.46(24)
|
Subordination Agreement, dated January 3, 2011.
|
10.47(24)
|
Notice of Conversion Election, dated January 3, 2011.
|
10.48(25)
|
Unsecured Convertible Promissory Note for $34,750, with Magna Group, LLC, dated May 16, 2011.
|
10.49(25)
|
Promissory Note for $139,728.82 with Magna Group, LLC, dated May 16, 2011.
|
10.50(25)
|
Securities Purchase Agreement with Magna Group, LLC, dated May 16, 2011.
|
10.51(25)
|
Subordination Agreement, dated May 16, 2011.
|
10.52(26)
|
Promissory Note for $139,728.82 with Lotus Funding Group, LLC, dated June 15, 2011.
|
10.53(26)
|
Partial Assignment and Modification Agreement, dated June 15, 2011.
|
10.54(26)
|
Subordination Agreement, dated June 15, 2011.
|
10.55(27)
|
Promissory Note for $140,380.21 with Greystone Capital Partners, dated July 8, 2011.
|
10.56(27)
|
Partial Assignment and Modification Agreement, dated July 8, 2011.
|
10.57 (28)
|
Subordination Agreement, dated July 8, 2011.
|
10.58 (29)
|
Promissory Note for $139,728.82 with Greystone Capital Partners, dated August 1, 2011.
|
10.59 (29)
|
Partial Assignment and Modification Agreement, dated August 1, 2011.
|
10.60 (29)
|
Subordination Agreement, dated August 1, 2011.
|
10.61 (30)
|
Promissory Note for $139,728.82 with Greystone Capital Partners, dated September 1, 2011.
|
10.62 (30)
|
Partial Assignment and Modification Agreement, dated September 1, 2011.
|
(1)
|
Incorporated by reference to the Company’s Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2007.
|
(2)
|
Incorporated by reference to Amendment No. 1 to the Company’s Form S-1 filed with the SEC on June 5, 2007.
|
(3)
|
Incorporated by reference to Amendment No. 2 to the Company’s Form S-1 filed with the SEC on July 12, 2007.
|
(4)
|
Incorporated by reference to Amendment No. 3 to the Company’s Form S-1 filed with the SEC on August 9, 2007.
|
(5)
|
Incorporated by reference to Amendment No. 4 to the Company’s Form S-1 filed with the SEC on September 6, 2007.
|
(6)
|
Incorporated by reference to Amendment No. 5 to the Company’s Form S-1 filed with the SEC on October 1, 2007.
|
(7)
|
Incorporated by reference to Post-effective Amendment No. 1 to the Company’s Form S-1 filed with the SEC on October 11, 2007.
|
(8)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 3, 2008.
|
(9)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2008.
|
(10)
|
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2008.
|
(11)
|
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2008.
|
(12)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on February 3, 2009.
|
(13)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 8, 2009.
|
(14)
|
Incorporated by reference to the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2009.
|
(15)
|
Incorporated by reference to the Company’s Annual Report on Form 10-K/A filed with the SEC on April 30, 2009.
|
(16)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 18, 2009.
|
(17)
|
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 20, 2009.
|
(18)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 9, 2009.
|
(19)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 3, 2009.
|
(20)
|
Incorporated by reference to Exhibit 4.6 to the Company’s Post-Effective Amendment to Registration Statement on Form S-8/A, filed with the SEC on June 2, 2010.
|
(21)
|
Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 6, 2010.
|
(22)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 29, 2010.
|
(23)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on December 6, 2010.
|
(24)
|
Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on January 12, 2011.
|
(25)
|
Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on May 25, 2011
|
(26)
|
Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on June 21, 2011
|
(27)
|
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15. 2011
|
(28)
|
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2011
|
(29)
|
Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on January 13, 2012
|
(30)
|
Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on January 30, 2012
|
(31)
|
Incorporated by reference to the Company Registration Statement on Form S-1/A filed with the SEC on February 8, 2012
|
(32)
|
Incorporated by reference to the Company Annual Report on Form 10-K filed with the SEC on March 29, 2013
|
(33)
|
Incorporated by reference to the Company Quarterly Report on Form 10-Q filed with the SEC on May 9, 2013
|
(34)
|
Incorporated by reference to the Company’s Registration Statement on Form S-1/A filed with the SEC on December 12, 2014.
|
(35)
|
Incorporated by reference to the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on December 19, 2014.
|
(36)
|
Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on October 2, 2015.
|
(37)
|
Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on November 4, 2015.
|
(38)
|
Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on December 4, 2015.
|
|
|
U.S. Stem Cell, Inc.
|
|
||
Date: May 4, 2016
|
By:
|
/s/ Mike Tomas
|
|
|
Mike Tomas
|
|
|
Chief Executive Officer &
|
|
|
President and Principal Financial
|
|
|
and Accounting Officer
|
1 Year US Stem Cell (CE) Chart |
1 Month US Stem Cell (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions